NCT05209841
Heparinization vs Salinization of the Peripheral Venous Catheter
StatusTerminated
PhaseNot applicable
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Poor recruitment Show 4 more changesShow less
- Final enrollment: 289 participants, 8% of the 3450 planned
- Eligibility criteria expanded, about 14 words
- Primary completion date changed from estimate of Jul 30, 2026 to Jul 10, 2025
- Site details revised
- Notable Primary and study completion dates: Jul 30, 2025 to Jul 30, 2026v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Jul 30, 2022 to Jul 30, 2025
- Start date changed from estimate of Mar 16, 2022 to Apr 5, 2022
- Site details revised
- Notable Start date: Jan 30, 2022 to Mar 16, 2022v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Percentage of obstructed catheters
Timeframe: From date of randomization through the date of hospital discharge, an average of 10 days.
Secondary (3)
Number of catheter-associated phlebitis
Number of catheter-associated bacterihemia episodes
Number of catheter loss due to extravasation
Arms and interventions
Catheter sealing with low dose heparinExperimental
Catheters will be sealed with 3mL of Fibrillin Ⓡ (heparin 20UI/mL)
Catheter sealing with normal salineActive comparator
Catheters will be sealed with 3mL of 0.9% sodium chloride
Drugs: Low dose heparin, Normal saline
Sites
1 site in 1 country
- Hospital Residència Sant CamilSant Pere de Ribes, Barcelona, Spain